2023-11-13T10:37:48-06:00 2022-12-31 410746749 CLIFTONLARSONALLEN LLP 293 EISENHOWER PARKWAY 2ND FLOOR LIVINGSTON NJ 07039 990 2022-01-01 208735688 SOLVING KIDS CANCER INC SOLV 2125886624 1 EAST 53RD STREET 8TH FLOOR NEW YORK NY 10022 SCOTT KENNEDY EXECUTIVE DIRECTOR 2125886624 2023-11-10 1 SCOTT KENNEDY 999009999 0 BRIDGET HARTNETT P01429163 9739949494 2023-11-10 3 AAL1 IAL1 2022 2023-04-26 12:10:37Z SCOTT KENNEDY 1 EAST 53RD STREET 8TH FLOOR NEW YORK NY 10022 1052308 0 X WWW.SOLVINGKIDSCANCER.ORG X 2006 NY MAKE RADICAL IMPROVEMENTS IN SURVIVAL OUTCOMES FOR CHILDREN WITH THE MOST FATAL PEDIATRIC CANCERS USING A PATIENT-CENTRIC APPROACH OF DRIVING/SUPPORTING HIGH-IMPACT CLINICAL RESEARCH, PRECLINICAL THERAPEUTIC DEVELOPMENT PROJECTS, CONDUCTING RESEARCH ADVOCACY IN THE LANDSCAPE AND EMPOWERING FAMILIES WITH RESOURCES/TOOLS TO HELP THEM NAVIGATE TREATMENT OPTIONS FOR THEIR CHILD. 11 10 5 17 0 0 691649 970445 0 0 7113 25663 -22029 -101841 676733 894267 503884 536079 0 0 448491 463712 54408 63253 241264 162491 146361 1169274 1209405 -492541 -315138 2774299 2595479 15861 152179 2758438 2443300 X SKC IMPACTS CHILDREN THROUGH THE INITIATION OF CLINICAL RESEARCH TRIALS OF INVESTIGATIONAL TREATMENT STRATEGIES. OUR VISION IS TO CONTINUE EXPANDING THE ARMAMENTARIUM OF EFFECTIVE AND LESS TOXIC TREATMENT STRATEGIES FOR PEDIATRIC ONCOLOGISTS TO UTILIZE UNTIL LONG-TERM SURVIVAL IS A REALITY FOR ALL CHILDREN WITH HIGH-RISK SOLID TUMORS AND BRAIN TUMORS.TO ACCOMPLISH OUR MISSION, SOLVING KIDS' CANCER FINDS, FUNDS AND ADVOCATES FOR BREAKTHROUGH TREATMENT OPTIONS TO CURE CHILDREN WITH THE MOST FATAL PEDIATRIC CANCERS THROUGH COLLABORATIVE PARTNERSHIPS WITH THE RESEARCH COMMUNITY AND RELATED NONPROFIT STAKEHOLDERS. 0 0 832355 536079 SKC AND OUR ADVISORS SURVEY, ACTIVELY DISCUSS AND PRIORITIZE THE AREAS OF GREATEST UNMET NEEDS WITHIN THE PEDIATRIC CANCER RESEARCH LANDSCAPE AND DEVELOP SPECIFIC PROGRAMS TO ADDRESS THEM. (1) THE PH I TITAN CLINICAL TRIAL IS PROVIDING AN EFFECTIVE TARGETED DRUG FOR CHILDREN WITH ALK MUTATIONS IN FRONTLINE TREATMENT WHEN NEWLY DIAGNOSED AND IS GENERATING CRITICAL DATA TOWARDS AN APPROVAL FOR USE AS A STANDARD OF CARE. WORKING TOWARDS HAVING THIS BE ONE OF THE FIRST TARGETED AGENTS BECOMING APPROVED FOR HR NB AND UTILIZED AS A COMBINATION THERAPY STRATEGY, MAKING A SIGNIFICANT IMPACT ON OVERALL SURVIVAL. (2) OUR COLLABORATION WITH THE NATIONAL CANCER INSTITUTE (NCI) TO VALIDATE AND DEVELOP AN IMMUNOTHERAPY TREATMENT FOR CHILDREN WITH ETMR BRAIN TUMORS USING A T-CELL CAR TO TARGET (CONTINUED ON SCH O) GPC2 IS THE FIRST-EVER IMMUNOTHERAPY RESEARCH PROGRAM SPECIFIC FOR ETMR BRAIN TUMORS. IF THE RESULTS ARE POSITIVE, THIS WORK WILL BE RAPIDLY TRANSLATED TO INCLUDE CHILDREN WITH ETMR IN A CLINICAL TRIAL USING THIS CUTTING-EDGE IMMUNOTHERAPY. (3) THE PH I CLIN TRIAL USING A TRIPLET COMBINATION HAS BEEN A LIFELINE FOR CHILDREN WITH NEUROBLASTOMA WHO RELAPSE AND THE STUDY HAS BEEN SO SUCCESSFUL THAT IT WILL STAY OPEN TO ACCRUE EVEN MORE PATIENTS THAN ORIGINALLY PLANNED. WHILE THE CLINICAL TRIAL IS PROVIDING TREATMENT BENEFIT TO PATIENTS, THE TRIAL IS GENERATING VERY IMPORTANT DATA THAT CAN BE USED TO FURTHER ADVANCE THIS TRIPLE TREATMENT COMBINATION INTO MORE POINTS IN THE TREATMENT CONTINUUM FOR EVEN GREATER PATIENT BENEFIT. (4) SKC TARGETS ONLY THE MOST CHALLENGING AND POOREST OUTCOME CHILDHOOD CANCERS THAT REQUIRE SIGNIFICANT HELP AND HAVE THE GREATEST UNMET NEED INCLUDING HIGH-RISK BRAIN TUMORS AND SOLID TUMORS. (5) TAKES A GLOBAL APPROACH TO SUPPORTING PROGRAMS TO LEVERAGE THE COLLECTIVE POWER OF COLLABORATION ACROSS SEVERAL CENTERS-OF-EXCELLENCE TO BREAK DOWN BARRIERS, SPEED PROGRESS AND HAVE MORE CHILDREN ACCESS PROMISING TREATMENTS. (6) PRIORITIZES ADVANCING TREATMENT OPTIONS THAT HAVE THE HIGHEST POTENTIAL FOR CURATIVE RESPONSES RATHER THAN PARTIAL TUMOR SHRINKAGE OR TEMPORARY LIFE EXTENSION. (7) TAKES LEADERSHIP ROLES WITHIN INFLUENTIAL NATIONAL AND INTERNATIONAL RESEARCH GROUPS' ADVISORY BOARDS AND CO-AUTHOR INFLUENTIAL PAPERS IN PROFESSIONAL JOURNALS TO DRIVE NEW DIRECTION TO POSITIVELY IMPACT PATIENTS. (8) BUILD COALITIONS AND PARTNERSHIPS WITH OTHER NONPROFITS IN COLLABORATIVELY DRIVING AND FUNDING RESEARCH PROJECTS FOR GREATER IMPACT AND SCALE BECAUSE WE ARE MUCH MORE EFFECTIVE TOGETHER THAN WORKING ALONE. SKC PRIORITIZES THE DELIVERY OF TRANSFORMATIVE, NEXT-GENERATION CANCER THERAPIES TO THIS POPULATION THAT INCLUDES IMMUNOTHERAPY {VACCINES, CELLULAR THERAPY, ONCOLYTIC VIROTHERAPY, THERAPEUTIC ANTIBODIES, CHECKPOINT INHIBITORS}, SYNERGISTIC COMBINATION TREATMENTS, NEW GENOMICALLY TARGETED DRUGS, INTERVENTIONAL RADIOLOGY TECHNIQUES AND NOVEL DELIVERY MECHANISMS. OUR CRITERIA FOR IDENTIFYING AND SUPPORTING THESE NOVEL APPROACHES AIMS TO PROVIDE MORE EFFECTIVE AND LESS TOXIC TREATMENT OPTIONS THAN THE CURRENT STANDARD-OF-CARE. (9) WE ARE PLANNING A NEW INITIATIVE FOR MEDULLOBLASTOMA TO IDENTIFY PROMISING COMBINATION THERAPIES THAT CROSS THE BLOOD-BRAIN BARRIER AS WELL AS NEW DELIVERY MECHANISMS. 832355 1 1 0 0 0 0 0 0 0 0 0 0 0 1 1 1 1 0 0 0 0 1 0 1 1 0 0 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 6 0 1 5 1 0 0 0 0 0 1 1 0 0 0 0 0 0 X 11 10 0 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 1 1 0 NY X THE ORGANIZATION 2125886624 1 EAST 53RD STREET 8TH FLOOR NEW YORK NY 10022 SCOTT KENNEDY EXECUTIVE DIRECTOR, CO-FOUNDER 40.00 X X 139094 0 20427 JOHN LONDON CHAIRMAN, CO-FOUNDER 2.00 X X 0 0 0 EYAL SOFFER TREASURER 2.00 X X 0 0 0 CHANNING STAVE PHD SECRETARY 2.00 X X 0 0 0 KHALIL BARRAGE DIRECTOR 2.00 X 0 0 0 HEARN JAY CHO MD DIRECTOR 2.00 X 0 0 0 MARK SAVOYE DIRECTOR 2.00 X 0 0 0 MICHAEL NIEDZIELSKI DIRECTOR 2.00 X 0 0 0 JULIA ROUX DIRECTOR 2.00 X 0 0 0 DIALA TABET DIRECTOR 2.00 X 0 0 0 LINDY GAD DIRECTOR 2.00 X 0 0 0 139094 0 20427 1 0 1 0 0 371877 598568 970445 25663 25663 56200 371877 158041 -101841 -101841 894267 0 0 -76178 469734 469734 15650 15650 50695 50695 159521 76907 40277 42337 254064 114742 70747 68575 20915 14426 1582 4907 29212 18151 1110 9951 42570 20543 6569 15458 63253 63253 31997 15380 4919 11698 8614 4156 1330 3128 2308 1272 309 727 5487 2646 847 1994 28042 13531 4328 10183 6854 4624 665 1565 5867 2832 905 2130 DUES AND SUBSCRIPTIONS 10032 4841 1548 3643 MISCELLANEOUS 2902 1401 447 1054 MEALS AND ENTERTAINMENT 1688 824 203 661 1209405 832355 135786 241264 380203 573869 2314177 1773840 69307 93245 7027 5804 3585 148721 2774299 2595479 15861 4926 0 147253 15861 152179 X 868512 726840 1889926 1716460 2758438 2443300 2774299 2595479 -315138 0 X X 0 1 X 1 0 X 1418138 1166474 831151 691649 970445 5077857 1418138 1166474 831151 691649 970445 5077857 531152 4546705 11326 57798 41436 7113 25663 143336 5221193 0.87080 0.89490 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 0 SECURITY DEPOSITS 1468 OPERATING LEASE RIGHT-OF-USE (ROU) ASSET 147253 148721 OPERATING LEASE LIABILITY 147253 147253 X 894267 0 894267 0 894267 1209405 0 1209405 0 1209405 PART X, LINE 2: THE ORGANIZATION FOLLOWS STANDARDS THAT PROVIDE CLARIFICATION ON ACCOUNTING FOR UNCERTAINTY IN INCOME TAXES RECOGNIZED IN THE ORGANIZATION'S FINANCIAL STATEMENTS. THE GUIDANCE PRESCRIBES A RECOGNITION THRESHOLD AND MEASUREMENT ATTRIBUTE FOR THE RECOGNITION AND MEASUREMENT OF A TAX POSITION TAKEN OR EXPECTED TO BE TAKEN IN A TAX RETURN, AND ALSO PROVIDES GUIDANCE ON DERECOGNITION, CLASSIFICATION, INTEREST AND PENALTIES, DISCLOSURE AND TRANSITION. THE ORGANIZATION'S POLICY IS TO RECOGNIZE INTEREST AND PENALTIES ON UNRECOGNIZED TAX BENEFITS IN INCOME TAX EXPENSE. NO INTEREST AND PENALTIES WERE RECORDED DURING 2022 AND 2021. AT DECEMBER 31, 2022 AND 2021, THERE ARE NO SIGNIFICANT INCOME TAX UNCERTAINTIES. 0 0 0 0 0 0 0 0 0 0 EUROPE CANCER RESEARCH 50695 CHECK 0 1 1 0 0 0 0 0 0 PART III ACCOUNTING METHOD: X X 1 STREETLIGHT DIGITAL 13396 LAFAYETTE WAY THORNTON CO 80241 SHOELACES ($25,784) AND YEAR-END APPEAL ($107,784) 0 133568 63253 70315 133568 63253 70315 NY SPRING CELEBRATION 376905 323155 53750 63973 32823 49370 SEPTEMBER CAMPAIGN 29802 29802 4018 1 21370 18920 2450 7857 428077 371877 56200 63973 32823 61245 158041 -101841 1 CHILDREN'S HOSPITAL OF PHILADELPHIA 3401 CIVIC CENTER BLVD PHILIDELPHIA PA 19104 231352166 501(C)(3) 322793 0 CASH CANCER RESEARCH BOSTON CHILDREN'S HOSPITAL 401 PARK DRIVE SUITE 602 BOSTON MA 02215 042774441 501(C)(3) 46941 0 CASH CANCER RESEARCH NATIONAL CANCER INSTITUTE 9000 ROCKVILLE PIKE BETHESDA MD 20814 131919715 100000 0 CASH CANCER RESEARCH 2 1 CANCER RESEARCH 1 15650 COST REPURPOSING LLC PART I, LINE 2: THE ORGANIZATION EXPENDS FUNDS IN CONNECTION WITH GRANT COMMITMENTS AS EACH GRANTEE ACCOMPLISHES SPECIFIC MILESTONES SET FORTH IN EACH GRANT AGREEMENT. EACH GRANTEE IS REQUIRED TO SUBMIT PROGRESS REPORTS ON A PERIODIC BASIS AS MILESTONES ARE ACHIEVED PURSUANT TO THE GRANT AGREEMENTS. IF FUNDS ARE NOT USED BY THE GRANTEE IN ACCORDANCE WITH THE AGREEMENT, FUNDS ARE RETURNED. X X X 0 0 0 0 0 0 0 0 0 SCOTT KENNEDY EXECUTIVE DIRECTOR, CO-FOUNDER 139094 0 0 0 0 0 0 0 20427 0 159521 0 0 0 PART I, LINE 3 FAIR MARKET VALUE COMPARISON OF SIMILAR ORGANIZATIONS FORM 990, PART VI, SECTION B, LINE 11B THE COMPLETED FORM 990 IS SENT TO THE BOARD OF DIRECTORS PRIOR TO FILING FOR REVIEW AND APPROVAL. FORM 990, PART VI, SECTION B, LINE 12C THE ORGANIZATION DISTRIBUTES A CONFLICT OF INTEREST POLICY TO EACH BOARD MEMBER ANNUALLY AT THE BOARD MEETING. ALL STAFF AND BOARD MEMBERS ARE REQUIRED TO SIGN A CONFLICT OF INTEREST POLICY STATEMENT. ANY CONFLICTS THAT ARISE DURING THE COURSE OF THE YEAR ARE REQUIRED TO BE DISCLOSED AND RESOLVED BEFORE THE TRANSACTION IS COMPLETED. FORM 990, PART VI, SECTION B, LINE 15 COMPENSATION IS DETERMINED BY CONDUCTING A FAIR MARKET VALUE COMPARISON OF OTHER ORGANIZATIONS BY THE BOARD CHAIR. FACTORS INCLUDE THE NUMBER OF HOURS WORKED AND THE BREADTH OF ROLES AND RESPONSIBILITIES. FORM 990, PART VI, SECTION C, LINE 18 THE ORGANIZATION'S FORM 990 IS AVAILABLE UPON REQUEST. FORM 990, PART VI, SECTION C, LINE 19 THE ORGANIZATION'S GOVERNING DOCUMENTS ARE MADE AVAILABLE UPON REQUEST. FORM 990, PART XII, LINE 2C: THE BOARD OF DIRECTORS IS CHARGED WITH OVERSIGHT IN REGARDS TO REVIEW OF THE FINANCIALS AND SELECTION OF THE AUDITOR. THE OVERSIGHT PROCESS HAS NOT CHANGED FROM THE PRIOR YEAR.